Off-label
An approved drug prescribed for something other than what it was approved for. Lawful, routine, and frequently confused with something quite different.
Off-label use is prescribing an FDA-approved drug outside the terms of its approval: for a different condition, at a different dose, by a different route, or in a different population than the labelling covers.
It is legal, it is common, and in several fields it is the norm rather than the exception. Large shares of prescribing in paediatrics and oncology are off-label, often because trials were never run in those populations rather than because anyone thinks the drug is inappropriate.
Why it is allowed
The FDA regulates the approval and marketing of drugs. It does not regulate the practice of medicine, which sits with state medical boards. A licensed prescriber may use an approved drug according to their judgment for a patient in front of them.
The asymmetry is in what may be said. A manufacturer may not promote a drug for an unapproved use, because promotion is regulated. A physician may prescribe for one. That is why a use can be widespread in practice while entirely absent from the product's labelling.
The distinction that matters most
Off-label and unapproved are routinely treated as the same thing and they are not.
An off-label prescription involves an approved drug. The molecule went through review. Its manufacturing is regulated under CGMP, its purity and identity are established, its safety profile is characterised, and it feeds the FDA's adverse-event reporting system. What is off-label is the indication.
An unapproved substance has none of that. A research chemical was never reviewed, is not made under an approved manufacturing standard, and has no labelling. Calling its use off-label is a category error, because there is no label to be off.
The two terms are often run together in marketing copy, and off-label sounds more regulated than unapproved does. Asking whether the substance itself is approved, separately from whether the use is, cuts through it. A compounded preparation is a third case again: not an approved product, though it may contain an approved drug substance.
What varies underneath the label
Off-label is a legal description and carries no information about evidence. The spectrum is wide.
- Well supported. Substantial published trials exist for the off-label use; the manufacturer simply never sought approval for it, often because the patent economics do not justify the trial.
- Supported by practice. Long clinical experience and observational data, without randomised evidence.
- Extrapolated. The use is inferred from mechanism or from a related population, with little direct evidence.
- Speculative. Little more than plausibility.
All four are described by the same two words. "It is prescribed off-label" is therefore not an argument that something works, and it is not an argument that it does not. It is a statement about paperwork, and the evidence question has to be asked separately.
That separation is what the compound library is for: every compound is graded on how much research actually exists, independent of its regulatory status.
What it changes in practice
Two consequences follow that are easy to miss.
Insurance frequently will not cover it. Coverage is usually tied to approved indications, so an off-label prescription is often paid out of pocket even when the drug itself is unremarkable and widely covered for something else.
The labelling does not describe your use. The dosing, the contraindications and the interaction warnings in the prescribing information were derived for the approved indication and population. They remain the best available information about the molecule, but they were not written about what it is being used for, and the monitoring appropriate to an off-label use may not appear anywhere in them. That is a question for the prescriber rather than for the leaflet.
Adverse-event reporting still applies, which is worth knowing: events on an approved drug reach FAERS regardless of whether the use was on-label. That is a real safety infrastructure, and it is precisely what is absent for unapproved substances.
Related terms: research chemical, compounded medication, FDA approval.
